Carsten Brockmeyer
The Power List 2016
![](/fileadmin/_processed_/6/3/csm_Brockmeyer-426-new_0e195e2179.png)
Carsten Brockmeyer
Chief Executive Officer, Formycon
Carsten has been working with the biosimilars industry from the very beginning; he was involved in the development of Binocrit (epoetin alfa), the world’s first complex biosimilar anemia drug. He was headhunted for the role at Formycon after holding a one-day workshop on biosimilars at the company.
![](/fileadmin/_processed_/0/2/csm_PL_2019-2015_3149562606.png)